MARLBOROUGH, Mass., and BERLIN, and YOKNEAM ILLIT, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) — ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, is pleased to announce the upcoming conference call to discuss Medicare’s preliminary payment determination for the ReWalk Personal Exoskeleton.
On November 29, 2023, the Healthcare Common Procedure Coding System (“HCPCS”) meeting, hosted by the Centers for Medicare & Medicaid Services (“CMS”), will convene to discuss the Medicare payment determination for the ReWalk Personal Prosthetic Exoskeleton system. The CMS has already provided a preliminary payment determination of $94,617, setting the stage for potentially significant changes in the field of mobility assistive technologies.
The conference call, scheduled for Wednesday, November 8, 2023, at 8:30 a.m. EST, will feature Larry Jasinski, Chief Executive Officer, Jeannine Lynch, Vice President of Market Access and Strategy, and Mike Lawless, Chief Financial Officer, who will delve into the potential impact of this exciting development. Analysts and investors can participate in the call using the following access codes: Toll-free (U.S.) 1-833-316-0561, International (U.S.) 1-412-317-0690, Germany 0800-6647650, and Israel 1-80-9212373.
The webinar will be simultaneously webcasted and can be accessed through a link on the Company’s website at rewalk.com, specifically in the “Investors” section. An archived webcast will also be available for those unable to attend the live session.
ReWalk Robotics Ltd. is dedicated to revolutionizing the lives of individuals with neurological conditions through the development of cutting-edge medical devices. With a wide range of market-leading technologies, ReWalk is committed to enhancing mobility and wellness in both rehabilitation and daily life. The recent addition of anti-gravity systems through the acquisition of AlterG, Inc. further expands ReWalk’s portfolio of products.
For more information about the ReWalk systems, please visit rewalk.com, and for information on the AlterG systems, please visit alterg.com.
FAQ:
Q: What is the preliminary payment determination for the ReWalk Personal Exoskeleton?
A: The Centers for Medicare & Medicaid Services (CMS) has determined a preliminary payment of $94,617 for the ReWalk Personal Exoskeleton system.
Q: When is the conference call scheduled?
A: The conference call is scheduled for Wednesday, November 8, 2023, at 8:30 a.m. EST.
Q: How can analysts and investors join the conference call?
A: Analysts and investors can participate in the conference call using the following access codes: Toll-free (U.S.) 1-833-316-0561, International (U.S.) 1-412-317-0690, Germany 0800-6647650, and Israel 1-80-9212373.
Q: Can the conference call be accessed online?
A: Yes, the conference call will be webcast live and can be accessed through a link on the Company’s website at rewalk.com or through this link: https://edge.media-server.com/mmc/p/664yxytg/.
Q: Will there be an archived webcast available?
A: Yes, an archived webcast will be available on the Company’s website for those unable to attend the live session.
Q: What is the mission of ReWalk Robotics Ltd.?
A: ReWalk Robotics Ltd. aims to fundamentally improve the quality of life for individuals with neurological conditions through the development of market-leading technologies that enable mobility and wellness.